Zacks Investment Research Lowers Allergy Therapeutics (AGYTF) to Sell

Share on StockTwits

Zacks Investment Research downgraded shares of Allergy Therapeutics (OTCMKTS:AGYTF) from a hold rating to a sell rating in a research report released on Wednesday.

According to Zacks, “Allergy Therapeutics Plc is a specialty pharmaceutical company focused on allergy vaccination. The company’s product pipeline consists of PollinexTrees(R), Pollinex Grasses + Rye(R), Skin Prick Testing, Diagnostic Products and Service. Allergy Therapeutics Plc is based in Worthing, the United Kingdom. “

Shares of OTCMKTS:AGYTF opened at $0.17 on Wednesday. The company has a quick ratio of 1.51, a current ratio of 2.11 and a debt-to-equity ratio of 0.10. Allergy Therapeutics has a 12-month low of $0.17 and a 12-month high of $0.19.

About Allergy Therapeutics

Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.

Further Reading: What are gap-up stocks?

Get a free copy of the Zacks research report on Allergy Therapeutics (AGYTF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with's FREE daily email newsletter.